Use of interleukin-6 (IL-6) inhibitors has been associated with mixed results in literature53 although a recent meta-analysis reported improved outcomes in COVID-19 patients receiving IL-6 inhibitors in combination with steroid therapy54. The gene discussed is IL6; the disease is COVID-19.